Transcription factors: Their potential as targets for an individualized therapeutic approach to cancer

Cancer Gene Therapy

Volumn 16, Issue 2, 2009, Pages 103-112

  Mees, C ^a   Nemunaitis, J ^a   Senzer, N ^a  

^a Mary Crowley Cancer Research Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; PROTEOME; RETINOIC ACID RECEPTOR ALPHA; RNA POLYMERASE II; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR PEA3; TRANSCRIPTION FACTOR POU4F2; TRANSCRIPTION FACTOR SP1; TRANSCRIPTOME;

ANGIOGENESIS; APOPTOSIS; CANCER GENE THERAPY; CANCER GROWTH; CANCER INVASION; CANCER RESEARCH; CELL SURVIVAL; COMPUTER MODEL; DNA TRANSCRIPTION; DRUG RESEARCH; DRUG SCREENING; ENHANCER REGION; GENE OVEREXPRESSION; GENOME; HUMAN; METABOLOME; METASTASIS POTENTIAL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; REVIEW; SIGNAL TRANSDUCTION; SILENCER ELEMENT; SILENCER GENE; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION FACTORS;

EID: 58349118904     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.73     Document Type: Review

References (102)

1. Laub MT, McAdams HH, Feldblyum T, Fraser CM, Shapiro L. Global analysis of the genetic network controlling a bacterial cell cycle. Science 2000; 290: 2144-2148.
2. Blais A, Dynlacht BD. Devising transcriptional regulatory networks operating during the cell cycle and differentiation using ChIP-on-chip. Chromosome Res 2005; 13: 275-288.
3. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet 2003; 12: 2249-2254.
4. Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O'Donovan MC. Strong bias in the location of functional promoter polymorphisms. Hum Mutat 2005; 26: 214-223.
5. Luscombe NM, Babu MM, Yu H, Snyder M, Teichmann SA, Gerstein M. Genomic analysis of regulatory network dynamics reveals large topological changes. Nature 2004; 431: 308-312.
6. Tuck DP, Kluger HM, Kluger Y. Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics 2006; 7: 236.
7. Thomas MC, Chiang CM. The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol 2006; 41: 105-178.
8. Maston GA, Evans SK, Green MR. Transcriptional regulatory elements in the human genome. Annu Rev Genomics Hum Genet 2006; 7: 29-59.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
10. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
11. Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002; 8: 1681-1694.
12. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 2004; 108: 181-188.
13. Brickman JM, Adam M, Ptashne M. Interactions between an HMG-1 protein and members of the Rel family. Proc Natl Acad Sci USA 1999; 96: 10679-10683.
14. Campisi J. Cellular senescence as a tumor suppressor mechanism. Trends Cell Biol 2001; 11: S27-S31.
15. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400.
16. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999; 13: 607-619.
17. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002; 21: 7680-7689.
18. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006; 6: 17-33.
19. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152: 1-9.
20. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-3015.
21. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
22. Crowe DL, Kim R, Chandraratna RA. Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathway. Mol Cancer Res 2003; 1: 532-540.
23. Chakravarti N, Mathur M, Bahadur S, Kumar Shukla N, Ralhan R. Retinoic acid receptor-alpha as a prognostic indicator in oral squamous cell carcinoma. Int J Cancer 2003; 103: 544-549.
24. Kaiser PC, Korner M, Kappeler A, Aebi S. Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol 2005; 16: 1477-1487.
25. Gyftopoulos K, Perimenis P, Sotiropoulou-Bonikou G, Sakellaropoulos G, Varakis I, Barbalias GA. Immunohistochemical detection of retinoic acid receptor-alpha in prostate carcinoma: correlation with proliferative activity and tumor grade. Int Urol Nephrol 2000; 32: 263-269.
26. van der Leede BM, Geertzema J, Vroom TM, Decimo D, Lutz Y, van der Saag PT et al. Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. Am J Pathol 1996; 148: 1905-1914.
27. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 2002; 16: 2699-2712.
28. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001; 277: 1-14.
29. Wasson JC, Saylors III RL, Zeltzer P, Friedman HS, Bigner SH, Burger PC et al. Oncogene amplification in pediatric brain tumors. Cancer Res 1990; 50: 2987-2990.
30. Lee WH, Murphree AL, Benedict WF. Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 1984; 309: 458-460.
31. Nau MM, Brooks Jr BJ, Carney DN, Gazdar AF, Battey JF, Sausville EA et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci USA 1986; 83: 1092-1096.
32. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H et al. N-myc oncogene overexpression downregulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene 2002; 21: 3552-3561.
33. Dennis JH, Budhram-Mahadeo V, Latchman DS. The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells. Oncogene 2001; 20: 4961-4971.
34. Budhram-Mahadeo V, Ndisang D, Ward T, Weber BL, Latchman DS. The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. Oncogene 1999; 18: 6684-6691.
35. Lee SA, Ndisang D, Patel C, Dennis JH, Faulkes DJ, D'Arrigo C et al. Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter. Cancer Res 2005; 65: 3072-3080.
36. Somasundaram K. Tumor suppressor p53: regulation and function. Front Biosci 2000; 5: D424-D437.
37. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004; 157: 247-270.
38. Iyer NG, Chin SF, Ozdag H, Daigo Y, Hu DE, Cariati M et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004; 101: 7386-7391.
39. Edelman J, Nemunaitis J. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr Opin Mol Ther 2003; 5: 611-617.
40. Menander K, Chada S, Zumstein L, Merrit J, Nemunaitis J, Clayman G et al. Clinical trials of Advexins p53 tumor suppressor therapy. Supplement. Clin Cancer Ther. (in press).
41. Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662.
42. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
43. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-362.
44. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005; 25: 7432-7440.
45. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-2008.
46. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24: 3236-3245.
47. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-954.
48. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002; 21: 8804-8816.
49. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003; 278: 27287-27292.
50. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
51. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 2001; 12: 3328-3339.
52. Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA, Weigel RJ. Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 2001; 276: 33554-33560.
53. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-253.
54. Im YH, Kim HT, Lee C, Poulin D, Welford S, Sorensen PH et al. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Cancer Res 2000; 60: 1536-1540.
55. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003; 63: 8338-8344.
56. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000; 60: 1211-1216.
57. Hogg A, Bia B, Onadim Z, Cowell JK. Molecular mechanisms of oncogenic mutations in tumors from patients with bilateral and unilateral retinoblastoma. Proc Natl Acad Sci USA 1993; 90: 7351-7355.
58. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53: 781-784.
59. Gouyer V, Gazzeri S, Brambilla E, Bolon I, Moro D, Perron P et al. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer 1994; 58: 818-824.
60. Sato Y. Transcription factor ETS-1 as a molecular target for angiogenesis inhibition. Hum Cell 1998; 11: 207-214.
61. Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res 2004; 64: 1338-1346.
62. Qin C, Wilson C, Blancher C, Taylor M, Safe S, Harris AL. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin Cancer Res 2001; 7: 818-823.
63. Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB. Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem 2001; 276: 25184-25189.
64. Dong Z, Nishiyama J, Yi X, Venkatachalam MA, Denton M, Gu S et al. Gene promoter of apoptosis inhibitory protein IAP2: identification of enhancer elements and activation by severe hypoxia. Biochem J 2002; 364(Part 2): 413-421.
65. Freeland K, Boxer LM, Latchman DS. The cyclic AMP response element in the Bcl-2 promoter confers inducibility by hypoxia in neuronal cells. Brain Res Mol Brain Res 2001; 92: 98-106.
66. Jean D, Bar-Eli M. Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy. Crit Rev Immunol 2001; 21: 275-286.
67. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 4143-4154.
68. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000; 60: 1546-1551.
69. Kitadai Y, Yasui W, Yokozaki H, Kuniyasu H, Haruma K, Kajiyama G et al. The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Biochem Biophys Res Commun 1992; 189: 1342-1348.
70. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger Met al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2002; 2: 35.
71. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005; 65: 1007-1017.
72. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64: 2030-2038.
73. Sporn MB. The war on cancer. Lancet 1996; 347: 1377-1381.
74. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A et al. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001; 7: 551-557.
75. Bieche I, Tozlu S, Girault I, Onody P, Driouch K, Vidaud M et al. Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 2004; 25: 405-411.
76. Gilliland DG. The diverse role of the ETS family of transcription factors in cancer. Clin Cancer Res 2001; 7: 451-453.
77. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997; 15: 1513-1525.
78. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res 2003; 9: 1412-1419.
79. Myers E, Hill ADK, Kelly G, McDermott EW, O'Higgins NJ, Young LS. A positive role for PEA3 in HER2-mediated breast tumor progression. Br J Cancer 2006; 95: 1404-1409.
80. Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, Hassell JA. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol 2001; 11: 1739-1748.
81. Liu Y, Borchert GL, Phang JM. Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J Biol Chem 2004; 279: 18694-18700.
82. Iwasaka C, Tanaka K, Abe M, Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996; 169: 522-531.
83. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987; 236: 582-585.
84. Chen Z, Fisher RJ, Riggs CW, Rhim JS, Lautenberger JA. Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res 1997; 57: 2013-2019.
85. Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci USA 1995; 92: 8754-8758.
86. Ko JH, Miyoshi E, Noda K, Ekuni A, Kang R, Ikeda Y et al. Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines. J Biol Chem 1999; 274: 22941-22948.
87. Pokholok DK, Zeitlinger J, Hannett NM, Reynolds DB, Young RA. Activated signal transduction kinases frequently occupy target genes. Science 2006; 313: 533-536.
88. Kel A, Voss N, Jauregui R, Kel-Margoulis O, Wingender E. Beyond microarrays: finding key transcription factors controlling signal transduction pathways. BMC Bioinformatics 2006; 7(Suppl 2): S13.
89. Janes KA, Yaffe MB. Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol 2006; 7: 820-828.
90. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92: 1388-1402.
91. Luo K, Yuan J, Shan Y, Li J, Xu M, Cui Y et al. Activation of transcriptional activities of AP1 and SRE by a novel zinc finger protein ZNF445. Gene 2006; 367: 89-100.
92. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007; 3: 166-173.
93. Eder I, Hoffman J, Rogatsch H, Schafer G, Zopf D, Bartsch G et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002; 9: 117-125.
94. Halmos B, Huettner C, Kocher O, Ferenczi K, Karp D, Tene D. Down-regulation and antiproliferative role of C/EBP in lung cancer. Cancer Res 2002; 62: 528-534.
95. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001; 414: 457-462.
96. Hashiya N, Jo N, Aoki M, Matsumoto K, Nakamura T, Sata Y et al. In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation 2004; 109: 3035-3041.
97. Lee R, Hench J, Ruvkun G. Regulation of C. elegans DAF-16 and its human ortholog FKHRL1 by the daf-2 insulin-like signaling pathway. Curr Biol 2001; 11: 1950-1957.
98. Vincent K, Shyu K, Luo Y, Magner M, Tio R, Jiang C et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1a/VP16 hybrid transcription factor. Circulation 2000; 102: 2255-2261.
99. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
100. Manshouri T, Yang Y, Lin H, Stass SA, Glassman AB, Keating MJ et al. Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma. Blood 1997; 89: 2507-2515.
101. Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC et al. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 2002; 21: 2846-2853.
102. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA et al. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001; 7: 2887-2897.